Russia won't ban Western drug imports until at least end-2018

5 June 2018
russia_li

The Russian national Parliament (State Duma), together with the government, will suspend introducing a ban on the imports of drugs from the USA and other ‘unfriendly’ Western states by at least the end of the current year, according to recent statements of some senior officials in the Russian government, including the Russian Health Minister Veronika Skvortsova, report The Pharma Letter’s local correspondent.

The ban on the import of drugs was decided to be removed from the bill on counter-sanctions, which was finally approved by the Russian government.

As a result of a sharp criticism from producers and Russian public community, the State Duma decided to soften the bill, removing the main controversial items from it, including the ban on drug imports to the country.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical